7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

CytoMed Therapeutics Limited
(NASDAQ:GDTC) 

GDTC stock logo

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D liga...

Founded: 2018
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
CytoMed Therapeutics Days Payable Outstanding ttm (DPO)
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 016.7733.5450.3167.0983.86100.63117.4
CytoMed Therapeutics Days Inventory Outstanding ttm (DIO)
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0250.01500.02750.031,000.041,250.061,500.071,750.08
CytoMed Therapeutics Op Cashflow Per Share ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.19-0.17-0.14-0.11-0.08-0.06-0.030
CytoMed Therapeutics Free Cashflow Per Share ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.24-0.2-0.17-0.14-0.1-0.07-0.03-0
CytoMed Therapeutics Cash Per Share ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.130.260.390.520.650.780.91
CytoMed Therapeutics (GAAP) P/E ratio ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -14.44-12.38-10.31-8.25-6.19-4.13-2.060
CytoMed Therapeutics P/B ratio ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 011.3422.6934.0345.3756.7268.0679.4
No extra charts and metrics for this ticker.